Israeli soldiers with PTSD show symptom reductions in an MDMA-assisted therapy study as researchers examine treatment effects after combat trauma

Israeli soldiers with post-traumatic stress disorder showed reduced symptoms in a study of MDMA-assisted therapy focused on combat-related trauma. The core subject is the potential clinical use of MDMA alongside psychotherapy for people whose PTSD has been difficult to treat with standard approaches. The reported findings center on symptom improvement among military participants, linking MDMA sessions with therapeutic support rather than stand-alone drug effects. That framing matters because MDMA-assisted therapy is being studied as a structured intervention that may help patients process traumatic memories, lower fear responses, and strengthen engagement with therapy. The wider significance lies in growing international interest in psychedelic medicine for severe mental health conditions. Evidence from soldiers or veterans carries particular weight because combat trauma is often chronic, disabling, and resistant to conventional treatment, making any credible reduction in PTSD symptoms clinically and socially important.